Introduction
Factor VIII (FVIII) is a plasma glycoprotein cofactor that accelerates the activation of factor X by FIXa in the core reaction of blood coagulation cascade. Hemophilia A is an X-linked, recessive bleeding disorder (Anatonarakis et al., 1985) , which affects 1 in 10,000 males, resulting in defective or deficient human clotting factor VIII molecules, necessitating exogenous replacement by either plasma-or recombinant-derived FVIII preparations. In an effort to avoid any further risk of unknown viral or hazardous element contamination from the human donor blood (Chan and Lembach, 1991) , there have been concerted efforts to develop a safe and biologically active recombi-nant rFVIII. FVIII is synthesized as a 2,351-aa single-chain glycoprotein of 280 kDa with the domain structure of A1-A2-B-A3-C1-C2 and it circulates as a series of metal ion-linked heterodimers that result from cleavages at B-A3 junction as well as additional cleavages within B domain. FVIII is converted to its active form, factor VIIIa, upon proteolytic cleavages by thrombin and is a heterotrimer composed of the A1, A2, and A3-C1-C2 subunits. A1 subunits of factor VIIIa terminates with 36 residue segment (Met 3 3 7 -A r g 3 7 2 ) rich in acidic residues. This segment is removed after cleavages at Arg 3 3 6 b y activated protein C (APC). Inactivation of FVIII occurs by proteolysis of FVIII subunits by APC which hydrolizes subunit protein at Arg 3 3 6 in the heavy chain and Arg 1 7 2 1 in the light chain. However, recent observation suggests that cleavage at Arg 1 7 1 9 or Arg 1 7 2 1 in the light chain may be unrelated to FVIII inactivation (Fay, 1993) . Numerous forms of rFVIII has been expressed as a biologically active rFVIII through eukaryotic expression system; i.e. the B-domain-deleted FVIII variants are undergoing clinical or preclinical trials and other factor VIII variants have been designed for treatment of particular clinical manifestation of hemophilia A patients. In the present study, site-directed mutagenesis of FVIII at Arg 336 to Gln 336 was performed in order to produce an inactivation resistant mutant rFVIII (rFVIII m ) to allow an extended stability in the physiological system. A mutant heavy chain of FVIII (FVIII-H m ; Arg 3 3 6 to Gln 3 3 6 ) a n d w i l d-type light chain FVIII (FVIII-L) were expressed i n Baculovirus-insect cell (Sf9) system and reconstitution of a biologically active rFVIII m from these subunits was carried out.
Materials and Methods

Site-directed mutagenesis of FVIII-H
In order to extend a physiological half-life of rFVIII, substitution of G to A at Arg 3 3 6 codon of FVIII cDNA was performed by PCR-associated site-specific mutagenesis (Figure 1 ). FVIII heavy chain (FVIII-H) cDNA corresponding to nucleotide No.1 through No. 2293 was PCR amplified from a cloned B-domain deleted FVIII cDNA plasmid (pSP64FVIII-B) using oligonucleotide primers containing specific restriction enzyme recognizing sites (sense primer: A C C GC T C G A GA C C AT G C A A ATA GA-3', antisense p r i m e r : Figure  2b ). Subcloning was carried out by the method described by Sambrook et al.(1989) . Site specific mutation of FVIII-H cDNA (G 1074 to A 1 0 7 4 ) was confirmed by DNA sequencing performed by the method of Sanger and Coulson(1978) .
Cotransfection of recombinant transfer vectors with viral DNA and expression of rFVIII subunits in insect cells
For the expression of rFVIII-H m and FVIII-L in the Baculovirus expression system, insect cells (Sf9) were seeded in 35-mm tissue culture dishes(1 1 0 6 ) and incubated at 27˚C for 4 h in 2 ml BacPAK Grace's medium. Old medium was removed from cells and 2 ml BacPAK G r a c e's basic medium was added to the dishes and incubated for another 30 min. pAcSG2-FVIII-H m (G 1074 to A 1 0 7 4 ) and pBacPA K 9-F V I I I-L recombinant transfer vectors (500 ng each) were cotransfected with 5 ml of p B a c PAK6 DNA (B s uI digest) into Sf9 insect cells according to the method described in the manual of Clontech Lab. Inc. The cells cotransfected with these vectors and viral DNA were cultured for 5 h at 27˚C and 1.5 ml of Grace's medium supplemented with 10% fetal bovine serum and antibiotics (Gentamycin) was added and cultured for 72 h at 27˚C. Recombinant Baculoviruses released from the cultured cells were harvested after 3 days and saved for plaque assay. 
Reconstitution of rFVIII
r F V I I I-H m and rFVIII-L were purified from insect cell extracts by anti-FVIII antibody conjugated Sepharose-4B affinity gel column chromatography as described previously (Oh et al., 1997) . Reconstitution of biologically active rFVIII m was carried out by adding an equimolar amount (200 nM) of the partially purified rFVIII-H m and rFVIII-L in the 20 mM Hepes buffer, pH 7.2, containing 400 mM NaCl, 40 mM CaCl 2 , 1.0 mM 2-mercaptoethanol, and 10% FVIII-free plasma, and allowed to incubate for 24 h at 4˚C. The association of rFVIII-H m with rFVIII-L was monitored by FVIII-heterodimer ELISA assay (Oh et al.,1997 ) and emergence of cofactor activity was monitored by using Coamatic FVIII assay kit [Carlebjok et al.(1987) ]. The reassociation constant for rFVIII-H m with rFVIII-L was determined according to the method of Lenting et al.(1994) . Total protein content was determined by Bradford method (Bradford,1976) and quantitative analysis of rFVIII-H m and FVIII-L was performed by sandwitch type ELISA method (Johnston and Thorpe, 1987) .
Western blot immunodetection of rFVIII subunits
Western blot analysis of rFVIII subunits was performed according to the method described by Burnette et al. (1981) . Cell lysates including rFVIII-H m and rFVIII-L expressed in insect cells were subjected to SDS PAGE (10%) according to the method of Laemmli (1970) , and proteins in the gel were electrotransferred onto nitrocellulose membrane. Immuno detection of rFVIII subunits was carried out according to ECL Western blotting protocol (Amersham, Buckinghamshire, UK) using mouse monoclonal antibody to FVIIIc and polyclonal antibody to FVIII-H (specific for Asn 1 6 9~ Arg 5 4 1 ) as primary antibodies and peroxidase-conjugated antibody to mouse IgG as secondary antibody.
Results
Site specific mutation of FVIII-H
Mutation of Arg 3 3 6 to Gln 3 3 6 at N-terminal side of A2 domain in FVIII-H has been achieved by PCR amplification of A2 domain of FVIII-H using the mutant primer and ligation of it to A1 domain of FVIII-H amplified with PCR. Insertion of FVIII-H m (G 1074 to A 1074 ) and FVIII-L cDNA sequences into Baculovirus transfer vectors (pAcSG2 and pBacPAK9 plasmids) were confirmed by restriction analysis of plasmids prepared from E. coli cells transformed with the respective recombinant plasmids (Figure 3a, 3b) . Substitution of nucleotide at A r g 3 3 6 codon (CGA) to Gln 3 3 6 (CAA) was verified by DNA sequencing (Figure 3c ).
Production of Baculoviruses expressing rFVIII subunits
Insect cells were cotransfected with recombinant transfer vectors carrying the FVIII-H m and FVIII-L cDNAs (pAcSG2-F V I I I-H m and pBacPA K 9-F V I I I-L) with B s uI digested linearized Baculovirus DNA (pBacPAK6) and were cultured for 72 h. Viruses released into the culture media were harvested and saved for the plaque assay. The plaque assay was performed after serial dilution of viral stock solution and viral titer of 2.5 1 0 7 pfu/ml was determined. The presence of FVIII-H m and FVIII-L sequences in recombinant viruses was confirmed by PCR amplification of the sequences corresponding to each subunits ( Figure  4 ).
Identification and quantitative determination of rFVIII subunits expressed in insect cells
rFVIII-H m and FVIII-L proteins expressed in insect cells (Sf9) were extracted by homogenizing with the FVIII b u ffer and identified by western blot immunodetection system ( Figure 5 ). The amounts of rFVIII-H m p r o t e i n present in the culture media and in the insect cell lysates were 8.0 ng/ml and 526.3 ng/10 6 cells, respectively, and the amount of rFVIII-L protein presented in the cultured media and cell lysates were 83.2 ng/ml and 457.7 ng/10 6 cells, respectively (Table 1) .
Reconstitution of biologically active rFVIII m
The reconstitution of a biologically active rFVIII m m o l e c u l e was carried out by combining an equimolar concentration (200 nM) of rFVIII-H m and rFVIII-L in 10% FVIII-f r e e plasma containing 40 mM CaCl 2 and allowed to incubate for 24 h at 4˚C. Cofactor activity of the reconstituted rFVIII m was 2.85 x 10 -2 units/mg of reconstituted plasma protein (table 2) . The stability of rFVIII m ( i n a c t i v a t i o n resistance) were assessed by measuring the cofactor activity in comparison with normal plasma by the in vitro incubation at 37˚C in the coagulation milieu for the time periods of 6, 12, and 24 h. Cofactor activity of rFVIII m was slightly increased while that activity of the normal human plasma was decreased steadily for the incubation period of 24 h at 37˚C. The reassociation constant (k a ) for the rFVIII-H m and rFVIII-L was determined as 35 M -1 .sec -1 .
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Cells were cultured for 4 h and then media were changed with the fresh one (4 ml) and cultured another 72 h. FVIII content was measured by ELISA and reference plasma was used a standard. All values are means of duplicate.
Advances in recombinant DNA technology have led to the successful cloning of both cDNA and genomic sequences of FVIII, and the availability of full length FVIII cDNA has made it possible to construct a vector for the expression of FVIII in mammalian cells (Toole et al., 1984; Wood et al., l984; Kaufman et al., 1988; Klein, 1991; Pittman et al .,1993) . FVIII has been known to be synthesized as a single polypeptide having a sequential domain of A1-A 2-B-A 3-C 1-C2 of which B domain is dispensable for the cofactor activity . The generation of active FVIII from the isolated subunits has been demonstrated (Nordfang and Ezben,1988) , and an efficient production of rFVIII by coexpression of the heavy and light chains in cell culture system has been attained (Yonemura et al.,1993) . In the present study, we have synthesized recombinant variant, rFVIII-H m , of which Arg 336 , a APC cleavage site, was substituted to Gln 3 3 6 in order to prevent APC induced cleavage and inactivation of rFVIII m . rFVIII-L was synthesized in the same system and assembled with rFVIII-H or rFVIII-H m to functional rFVIII or rFVIII m . Both reconstituted rFVIII and rFVIII m had similar cofactor activities in a molar base, but rFVIII m retained relatively higher cofactor activity than that of rFVIII when they were incubated at 37˚C for 24 h. The high level of r F V I I I m cofactor activity during the incubation period was likely due to the loss of APC attacking site in rFVIII-H although inadequate amount of inactivating factors in the reconstituted rFVIII m pre-paration has not been ruled out. The lower clearance rate and the longer half-life of rFVIII than that of the highly purified plasma-based FVIII preparation in circulating blood have been reported (Morfini et al.,1992 (Morfini et al., , 1993 . In their report, the half-life of rFVIII in hemophilia patients was 14.6 ± 7.6 h while that of von Willebrand disease was 4.5 h, indicating that the half-life of rFVIII was much influenced by the presence of von Willebrand factor, a stabilizing molecules in blood. The relatively higher cofactor activity of rFVIII m in this study implicates that rFVIII m may be useful for the particular hemorrhagic diathesis in some hemophilia A patients. Activation process of FVIII is known to involve the limited proteolytic cleavage of single chain FVIII by specific proteases, thrombin and FXa (Harris et al. , l986) and further pro-teolysis of heavy chain of FVIII by thrombin and APC inactivates FVIII (Eaton et al., 1986; Fass, 1991) . Thus, it is expected that limitation of inactivating process by site-directed mutagenesis of its cDNA may improve the pharmacokinetic characteristics. The stability of both wild type FVIII and rFVIII m measured in our study was somewhat higher than the previous in vivo data of Morfini et al.(1992) . The d i fference between these two results might be due to the different assay systems (in vitro system vs in vivo system) and the quality of products used. The protection of rFVIII m from APC-mediated inactivation may have a sparing effect of rFVIII infused i n t o hemophilia A patients but the side effects associated with thrombophilia which is frequently observed in abnormal Factor V accumulation due to APC resistance should be considered. In fact, rFVIII m application may not be a serious risk factor for thrombophilia since FVIII resistance to APC did not cause thrombophilia (Ingerslev et al., 1996) . The benefits of rFVIII for the treatment of previously untreated patients with hemophilia A have been shown to outweigh the risks associated with inhibitor antibodies (Lusher et al. , 1993) . It is known that glycoproteins produced in insect cells are smaller in size than those of mammalian cells due to the presence of high mannose-type, small oligosaccharides in the molecules (Luckow, 1991) . r F V I I I m produced in insect cells in the present study could reassemble functionally active molecules with similar cofactor activity produced in other eukaryotic cell expression system (Yonemura et al., 1993) . These results indicate that size of oligo-saccharides in rFVIII may not be critical for the activity. The molecular weights of rFVIII-H m and rFVIII-L produced in Sf9 cells in the present study were close to 81 kDa which is the size to be expected (Figure 4) . The appear-ance of FVIII with heterogeneous size was thought to be due to the partial processing or degradation of the products in normal human plasma. It is likely that cofactor activity and stability of rFVIII m , obtained from individual subunits ( r F V I I I-H m , rFVIII-L) expressed in insect cell s y s t e m might be influenced by the presence of stabilizers in cells as well as in media. Therefore, optimization of rFVIII expression system in insect cell by coexpression of rFVIII subunits and vWF may lead to the yield of a biologically active rFVIII with better stability. In summary, functionally active and relatively stable r F V I I I m was produced by site-directed mutagenesis at G 1074 of FVIII-H cDNA (Arg 336 to Gln 336 ) and reconstitution of it from rFVIII-H m and rFVIII-L expressed in baculovirus insect cell system. Further study is required for the safety of the product in terms of thrombophilia due to APC resistance and biological half-life of the product in vivo.
